NICOTROL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NICOTROL (NICOTROL).
Nicotine is a nicotinic acetylcholine receptor agonist. It binds to and activates nicotinic acetylcholine receptors in the brain, leading to dopamine release and other neurotransmitter effects that mediate nicotine dependence and withdrawal symptoms.
| Metabolism | Primarily hepatic via CYP2A6, CYP2B6, and CYP2E1; also undergoes N-oxidation and glucuronidation. |
| Excretion | Primarily renal (10-20% unchanged; 80-90% as metabolites, mainly cotinine and nicotine-N'-oxide). Biliary/fecal excretion accounts for <10%. |
| Half-life | 2 hours (range 1-4 h). Shorter in smokers due to induction of metabolism; prolonged in renal impairment. |
| Protein binding | 5-20% (primarily to albumin). |
| Volume of Distribution | 1-2 L/kg (suggests extensive tissue distribution). |
| Bioavailability | Inhalation: ~50-80% (dose-dependent, with variability). Buccal: ~50-80%. Transdermal: ~80% (continuous absorption). |
| Onset of Action | Inhalation: rapid (within minutes). Buccal: 15-30 minutes. Transdermal: 2-4 hours. |
| Duration of Action | Inhalation: 30-60 minutes. Buccal: 2-3 hours. Transdermal: 24 hours. |
Inhalation: 1 cartridge (4 mg) inhaled as needed for craving relief, up to 16 cartridges per day; typical initial dose: 4-8 cartridges per day, with weaning over 12 weeks.
| Dosage form | SPRAY, METERED |
| Renal impairment | No specific dose adjustment recommended for renal impairment; use with caution in severe renal dysfunction due to potential nicotine accumulation. |
| Liver impairment | No specific Child-Pugh-based adjustments; nicotine clearance decreased in severe hepatic impairment; use with caution and monitor for adverse effects. |
| Pediatric use | Not approved for use in pediatric patients (<18 years). Safety and efficacy not established. |
| Geriatric use | No specific dose adjustments; use with caution due to increased sensitivity and comorbid conditions; monitor for side effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NICOTROL (NICOTROL).
| Breastfeeding | Nicotine is excreted in breast milk; M/P ratio approximately 2.0. Concentrations in milk exceed plasma. Avoid during breastfeeding due to risk of nicotine toxicity (vomiting, diarrhea, respiratory distress) and potential long-term effects on infant development. |
| Teratogenic Risk | Nicotine is a known teratogen. First trimester: increased risk of congenital malformations (e.g., cleft lip/palate, neural tube defects). Second/third trimester: impaired fetal growth, preterm birth, stillbirth. Nicotine causes placental vasoconstriction and fetal hypoxia. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to nicotine or any component of the product; patients with recent myocardial infarction (within 2 weeks), serious arrhythmias, or severe or worsening angina pectoris; patients with active temporomandibular joint disease (for gum formulation); patients with known soy or egg allergies (for certain formulations).
| Precautions | Use with caution in patients with cardiovascular disease, hypertension, hyperthyroidism, diabetes, or peptic ulcer; may cause allergic reactions including angioedema; risk of nicotine toxicity if used concomitantly with other nicotine products; should not be used in patients with life-threatening arrhythmias or severe or worsening angina; taper dose gradually to avoid withdrawal symptoms. |
Loading safety data…
| Fetal Monitoring |
| Monitor fetal growth (serial ultrasound), amniotic fluid index, fetal heart rate patterns. Assess maternal blood pressure and oxygen saturation. Monitor for signs of nicotine toxicity in mother (nausea, dizziness, tachycardia). |
| Fertility Effects | Nicotine negatively impacts fertility: reduces sperm count and motility in males, decreases ovarian reserve and alters menstrual cycle in females. May increase time to pregnancy and risk of infertility. |